{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:47:40Z","timestamp":1792799260630,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s40265-015-0438-2","type":"journal-article","created":{"date-parts":[[2015,7,15]],"date-time":"2015-07-15T08:30:59Z","timestamp":1436949059000},"page":"1293-1303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Recombinant Human Parathyroid Hormone (1\u201384): A Review in Hypoparathyroidism"],"prefix":"10.1007","volume":"75","author":[{"given":"Esther S.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian M.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,16]]},"reference":[{"key":"438_CR1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-88-470-5376-2_3","volume-title":"Hypoparathyroidism","author":"G Isaia","year":"2015","unstructured":"Isaia G, Marchetti M. PTH and PTH-related peptides. In: Brandi ML, Brown EM, editors. Hypoparathyroidism. Milan: Springer; 2015. p. 19\u201324."},{"issue":"10","key":"438_CR2","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/jbmr.483","volume":"26","author":"JP Bilezikian","year":"2011","unstructured":"Bilezikian JP, Khan A, Potts JT Jr, et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011;26(10):2317\u201337.","journal-title":"J Bone Miner Res."},{"key":"438_CR3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-88-470-5376-2_11","volume-title":"Hypoparathyroidism","author":"PD Pajevic","year":"2015","unstructured":"Pajevic PD, Wein MN, Kronenberg HM. Parathyroid hormone actions on bone and kidney. In: Brandi ML, Brown EM, editors. Hypoparathyroidism. Milan: Springer; 2015. p. 99\u2013109."},{"issue":"4","key":"438_CR4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMcp0803050","volume":"359","author":"D Shoback","year":"2008","unstructured":"Shoback D. Clinical practice. Hypoparathyroidism. N Engl J Med. 2008;359(4):391\u2013403.","journal-title":"N Engl J Med."},{"issue":"2","key":"438_CR5","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1590\/S0004-27302010000200019","volume":"54","author":"MR Rubin","year":"2010","unstructured":"Rubin MR, Bilezikian JP. Hypoparathyroidism: clinical features, skeletal microstructure and parathyroid hormone replacement. Arq Bras Endocrinol Metabol. 2010;54(2):220\u20136.","journal-title":"Arq Bras Endocrinol Metabol."},{"issue":"12","key":"438_CR6","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/jbmr.2004","volume":"28","author":"J Powers","year":"2013","unstructured":"Powers J, Joy K, Ruscio A, et al. Prevalence and incidence of hypoparathyroidism in the United States using a large claims database. J Bone Miner Res. 2013;28(12):2570\u20136.","journal-title":"J Bone Miner Res."},{"issue":"12","key":"438_CR7","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1359\/jbmr.080803","volume":"23","author":"MR Rubin","year":"2008","unstructured":"Rubin MR, Dempster DW, Zhou H, et al. Dynamic and structural properties of the skeleton in hypoparathyroidism. J Bone Miner Res. 2008;23(12):2018\u201324.","journal-title":"J Bone Miner Res."},{"key":"438_CR8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-88-470-5376-2_14","volume-title":"hypoparathyroidism","author":"BL Clarke","year":"2015","unstructured":"Clarke BL. Epidemiology of hypoparathyroidism. In: Brandi ML, Brown EM, editors. hypoparathyroidism. Milan: Springer; 2015. p. 139\u201354."},{"key":"438_CR9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-88-470-5376-2_15","volume-title":"Hypoparathyroidism","author":"AL Wheeler","year":"2015","unstructured":"Wheeler AL, Shoback DM. Clinical presentation of hypoparathyroidism. In: Brandi ML, Brown EM, editors. Hypoparathyroidism. Milan: Springer; 2015. p. 155\u201365."},{"issue":"9","key":"438_CR10","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1210\/jc.2008-1216","volume":"93","author":"MJ Horwitz","year":"2008","unstructured":"Horwitz MJ, Stewart AF. Hypoparathyroidism: is it time for replacement therapy? J Clin Endocrinol Metab. 2008;93(9):3307\u20139.","journal-title":"J Clin Endocrinol Metab."},{"key":"438_CR11","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/978-1-60327-478-4_30","volume-title":"Immunoendocrinology: scientific and clinical aspects","author":"OI Egbuna","year":"2011","unstructured":"Egbuna OI, Brown EM. Hypoparathyroidism. In: Eisenbarth GS, editor. Immunoendocrinology: scientific and clinical aspects. New York: Humana Press; 2011. p. 501\u201317."},{"key":"438_CR12","unstructured":"US FDA. FDA briefing document for the September 12, 2014 meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. 2014. http:\/\/www.fda.gov\/ . Accessed 22 June 2015."},{"issue":"2","key":"438_CR13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1530\/eje.0.1460215","volume":"146","author":"W Arlt","year":"2002","unstructured":"Arlt W, Fremerey C, Callies F, et al. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol. 2002;146(2):215\u201322.","journal-title":"Eur J Endocrinol."},{"key":"438_CR14","unstructured":"US FDA. Natpara\u00ae (parathyroid hormone) for injection: US prescribing information. 2015. http:\/\/www.fda.gov\/ . Accessed 22 June 2015."},{"issue":"Suppl 102s","key":"438_CR15","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1038\/sj.ki.5001599","volume":"70","author":"P D\u2019Amour","year":"2006","unstructured":"D\u2019Amour P. Circulating PTH molecular forms: what we know and what we don\u2019t. Kidney Int Suppl. 2006;70(Suppl 102s):S29\u201333.","journal-title":"Kidney Int Suppl."},{"key":"438_CR16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-88-470-5376-2_8","volume-title":"Hypoparathyroidism","author":"D Goltzman","year":"2015","unstructured":"Goltzman D, Karaplis AC. The PTH\/vitaminD\/FGF23 axis. In: Brandi ML, Brown EM, editors. Hypoparathyroidism. Milan: Springer; 2015. p. 69\u201379."},{"issue":"5","key":"438_CR17","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.clinthera.2014.04.001","volume":"36","author":"BL Clarke","year":"2014","unstructured":"Clarke BL, Kay Berg J, Fox J, et al. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1\u201384) in patients with hypoparathyroidism: an open-label, single-dose, phase I study. Clin Ther. 2014;36(5):722\u201336.","journal-title":"Clin Ther."},{"issue":"10","key":"438_CR18","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1002\/jbmr.1964","volume":"28","author":"T Sikjaer","year":"2013","unstructured":"Sikjaer T, Amstrup AK, Rolighed L, et al. PTH(1\u201384) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment. J Bone Miner Res. 2013;28(10):2232\u201343.","journal-title":"J Bone Miner Res."},{"issue":"10","key":"438_CR19","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/jbmr.470","volume":"26","author":"T Sikjaer","year":"2011","unstructured":"Sikjaer T, Rejnmark L, Rolighed L, et al. The effect of adding PTH(1\u201384) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res. 2011;26(10):2358\u201370.","journal-title":"J Bone Miner Res."},{"issue":"4","key":"438_CR20","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/jbmr.1493","volume":"27","author":"T Sikjaer","year":"2012","unstructured":"Sikjaer T, Rejnmark L, Thomsen JS, et al. Changes in 3-dimensional bone structure indices in hypoparathyroid patients treated with PTH(1\u201384): a randomized controlled study. J Bone Miner Res. 2012;27(4):781\u20138.","journal-title":"J Bone Miner Res."},{"issue":"11","key":"438_CR21","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1002\/jbmr.452","volume":"26","author":"MR Rubin","year":"2011","unstructured":"Rubin MR, Dempster DW, Sliney J Jr, et al. PTH(1\u201384) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J Bone Miner Res. 2011;26(11):2727\u201336.","journal-title":"J Bone Miner Res."},{"issue":"1","key":"438_CR22","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1210\/jc.2009-2682","volume":"96","author":"MR Rubin","year":"2011","unstructured":"Rubin MR, Manavalan JS, Dempster DW, et al. Parathyroid hormone stimulates circulating osteogenic cells in hypoparathyroidism. J Clin Endocrinol Metab. 2011;96(1):176\u201386.","journal-title":"J Clin Endocrinol Metab."},{"key":"438_CR23","unstructured":"US FDA. Natpara (parathyroid hormone) clinical pharmacology biopharmaceutics review. 2015. http:\/\/www.fda.gov\/ . Accessed 22 June 2015."},{"issue":"5","key":"438_CR24","doi-asserted-by":"crossref","first-page":"F975","DOI":"10.1152\/ajprenal.00336.2005","volume":"290","author":"PA Friedman","year":"2006","unstructured":"Friedman PA, Goodman WG. PTH(1\u201384)\/PTH(7-84): a balance of power. Am J Physiol Renal Physiol. 2006;290(5):F975\u201384.","journal-title":"Am J Physiol Renal Physiol."},{"issue":"7","key":"438_CR25","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1373\/clinchem.2003.030759","volume":"50","author":"SA Santini","year":"2004","unstructured":"Santini SA, Carrozza C, Vulpio C, et al. Assessment of parathyroid function in clinical practice: which parathyroid hormone assay is better? Clin Chem. 2004;50(7):1247\u201350.","journal-title":"Clin Chem."},{"key":"438_CR26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-88-470-5376-2_4","volume-title":"Hypoparathyroidism","author":"P D\u2019Amour","year":"2015","unstructured":"D\u2019Amour P. PTH assays and their clinical significance. In: Brandi ML, Brown EM, editors. Hypoparathyroidism. Milan: Springer; 2015. p. 25\u201332."},{"issue":"4","key":"438_CR27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","volume":"1","author":"M Mannstadt","year":"2013","unstructured":"Mannstadt M, Clarke BL, Vokes T, et al. Efficacy and safety of recombinant human parathyroid hormone (1\u201384) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol. 2013;1(4):275\u201383.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"10","key":"438_CR28","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1210\/jc.2014-2267","volume":"99","author":"NE Cusano","year":"2014","unstructured":"Cusano NE, Rubin MR, McMahon DJ, et al. PTH(1\u201384) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. J Clin Endocrinol Metab. 2014;99(10):3694\u20139.","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"438_CR29","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1210\/jc.2013-1239","volume":"98","author":"NE Cusano","year":"2013","unstructured":"Cusano NE, Rubin MR, McMahon DJ, et al. The effect of PTH(1\u201384) on quality of life in hypoparathyroidism. J Clin Endocrinol Metab. 2013;98(6):2356\u201361.","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"438_CR30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1210\/jc.2012-2984","volume":"98","author":"NE Cusano","year":"2013","unstructured":"Cusano NE, Rubin MR, McMahon DJ, et al. Therapy of hypoparathyroidism with PTH(1\u201384): a prospective four-year investigation of efficacy and safety. J Clin Endocrinol Metab. 2013;98(1):137\u201344.","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"438_CR31","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00198-009-1149-x","volume":"21","author":"MR Rubin","year":"2010","unstructured":"Rubin MR, Sliney J Jr, McMahon DJ, et al. Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos Int. 2010;21(11):1927\u201334.","journal-title":"Osteoporos Int."},{"key":"438_CR32","unstructured":"US FDA. Natpara (parathyroid hormone) medical review. 2015. http:\/\/www.fda.gov\/ . Accessed 22 June 2015."},{"key":"438_CR33","doi-asserted-by":"crossref","unstructured":"Clarke BL, Mannstadt M, Vokes TJ, et al. Three-year safety and efficacy data for recombinant human parathyroid hormone, rhPTH(1\u201384), in the treatment of adults with hypoparathyroidism: the RACE study [abstract no. OC3.5]. In: 17th European Congress of Endocrinology; 2015.","DOI":"10.1530\/endoabs.37.OC3.5"},{"key":"438_CR34","unstructured":"Levine MA, Bilezikian JP, Clarke BL, et al. Long-term effects of recombinant human parathyroid hormone, rhPTH(1\u201384), on bone remodelling in patients with hypoparathyroidism: 3-year data from the open-label RACE study [abstract no. P82 plus poster]. In: 4th joint meeting of ECTS and IBMS; 2015."},{"key":"438_CR35","doi-asserted-by":"crossref","unstructured":"Lakatos P, Bajnok L, Lagast H, et al. The REPEAT Study: an open-label clinical trial evaluating the safety and efficacy of recombinant human parathyroid hormone, rhPTH (1\u201384), for the treatment of hypoparathyroidism in Hungary [abstract no. OC6.4]. In: 16th European Congress of Endocrinology; 2014.","DOI":"10.1530\/endoabs.35.OC6.4"},{"issue":"6","key":"438_CR36","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s00198-014-2677-6","volume":"25","author":"T Sikjaer","year":"2014","unstructured":"Sikjaer T, Rolighed L, Hess A, et al. Effects of PTH(1\u201384) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporos Int. 2014;25(6):1717\u201326.","journal-title":"Osteoporos Int."},{"key":"438_CR37","unstructured":"NPS Pharma. FDA approves Natpara\u00ae (parathyroid hormone) for injection as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. 2015. http:\/\/ir.npsp.com\/releasedetail.cfm?releaseid=892722 . Accessed 22 June 2015."},{"key":"438_CR38","unstructured":"European Medicines Agency. Public summary of opinion on orphan designation\u2014recombinant human parathyroid hormone for the treatment of hypoparathyroidism. 2014. http:\/\/www.ema.europa.eu . Accessed 22 June 2015."},{"key":"438_CR39","unstructured":"NPS Pharma. European Medicines Agency validates marketing authorization application for Natpar\u00ae (parathyroid hormone (rDNA)) in hypoparathyroidism. 2014. http:\/\/ir.npsp.com\/releasedetail.cfm?releaseid=885657 . Accessed 22 June 2015."},{"issue":"18","key":"438_CR40","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.2165\/00003495-200666180-00008","volume":"66","author":"MD Moen","year":"2006","unstructured":"Moen MD, Scott LJ. Recombinant full-length parathyroid hormone (1\u201384). Drugs. 2006;66(18):2371\u201381.","journal-title":"Drugs."},{"key":"438_CR41","unstructured":"European Medicines Agency. Public statement on Preotact (PTH (parathyroid hormone)). 2014. http:\/\/www.ema.europa.eu\/ . Accessed 22 June 2015."},{"issue":"11","key":"438_CR42","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/BF03346763","volume":"36","author":"NE Cusano","year":"2013","unstructured":"Cusano NE, Rubin MR, Irani D, et al. Use of parathyroid hormone in hypoparathyroidism. J Endocrinol Invest. 2013;36(11):1121\u20137.","journal-title":"J Endocrinol Invest."},{"key":"438_CR43","author":"Y Ramakrishnan","year":"2015","unstructured":"Ramakrishnan Y, Cocks HC. Impact of recombinant PTH on management of hypoparathyroidism: a systematic review. Eur Arch Otorhinolaryngol. 2015;. doi: 10.1007\/s00405-014-3484-6 .","journal-title":"Eur Arch Otorhinolaryngol."},{"issue":"12","key":"438_CR44","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1002\/jbmr.1768","volume":"27","author":"EB Andrews","year":"2012","unstructured":"Andrews EB, Gilsenan AW, Midkiff K, et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res. 2012;27(12):2429\u201337.","journal-title":"J Bone Miner Res."},{"issue":"12","key":"438_CR45","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1002\/jbmr.1800","volume":"27","author":"C Cipriani","year":"2012","unstructured":"Cipriani C, Irani D, Bilezikian JP. Safety of osteoanabolic therapy: a decade of experience. J Bone Miner Res. 2012;27(12):2419\u201328.","journal-title":"J Bone Miner Res."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0438-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0438-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0438-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T01:37:53Z","timestamp":1599269873000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0438-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["438"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0438-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}